News On TCR2 Therapeutics Inc. (TCRR) Now Under ADAP
News On TCR2 Therapeutics Inc. (TCRR) Now Under ADAP
Adaptimmune Completes Merger With Fellow Immunology Company TCR2
Adaptimmune Announces Completion of Strategic Combination With TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 1, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced completion of an all-stock transaction in which Adaptimmune has combined with TCR2 Therapeutics Inc. (NASDAQ: TCRR) to create a preeminent T-cell therapy company to treat solid tumors.
Shareholders of TCR2 Therapeutics (TCRR.US) increased their common stock holdings by 50,000 shares, worth about US$86,000
On May 31, it was reported that according to documents disclosed by the US Securities and Exchange Commission (SEC) on May 30, $TCR2 Therapeutics (TCRR.US) $shareholder TANG KEVIN C increased its common stock holdings at an average price of 1.72 US dollars per share on May 25, worth about 86,000 US dollars. The transaction involved other related parties: TANG CAPITAL MANAGEMENT LLC and TANG CAPITAL PARTNERS LP. Image source: SEC's official website What is a change in shareholding
TCR2 Therapeutics Target Price Raised to $2.11 From $1.72 at Mizuho Securities
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in pe
TCR2 Therapeutics (TCRR) Receives a Hold From Mizuho Securities
TCR2 Therapeutics GAAP EPS of -$1.03 Misses by $0.34
TCR2 Therapeutics 1Q Loss/Shr $1.03 >TCRR
TCR2 Therapeutics 1Q Loss/Shr $1.03 >TCRR
Press Release: TCR(2) Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
TCR(2) Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights About 250+ Companies and 300+ Drugs
FUBO, MULN and BAK Are Among Pre-market Gainers
Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones jumped more than 500 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, ROCC, TCRR
Fate Therapeutics (NASDAQ:FATE) and TCR2 Therapeutics (NASDAQ:TCRR) Head to Head Comparison
Fate Therapeutics (NASDAQ:FATE – Get Rating) and TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two busine
TCR2 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR2 Therapeutics Inc. - TCRR
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of TCR2 Therapeutic
Head to Head Analysis: Fate Therapeutics (NASDAQ:FATE) & TCR2 Therapeutics (NASDAQ:TCRR)
TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) and Fate Therapeutics (NASDAQ:FATE – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two compan
Adaptimmune, TCR Therapeutics Set May 30 for Shareholder Votes on Deal
Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Risky
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR
NEW YORK, April 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache
No Data